Pages that link to "Q83598311"
Jump to navigation
Jump to search
The following pages link to Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria (Q83598311):
Displaying 11 items.
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis? (Q26801550) (← links)
- Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist (Q33964630) (← links)
- Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis (Q35446549) (← links)
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod (Q36097847) (← links)
- Future MS care: a consensus statement of the MS in the 21st Century Steering Group (Q36592674) (← links)
- MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials (Q37964985) (← links)
- Treatment update in multiple sclerosis (Q37996859) (← links)
- Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis (Q38262622) (← links)
- Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord. (Q48284501) (← links)
- Olig2-Targeted G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Survival in Response to Lysolecithin-Induced Demyelination. (Q48305321) (← links)
- Alemtuzumab: a further option for treatment of multiple sclerosis (Q82261906) (← links)